Answers are grounded in this paper and cite their sources.
Microbiological commentary reports rising serotype 35B and multidrug resistance in Streptococcus pneumoniae, highlighting limitations of capsule-targeting vaccines.
Streptococcus pneumoniae has demonstrated a remarkable ability to adapt during the conjugate vaccine era. The increasing incidence of serotype 35B disease and emergence of a multidrug-resistant clone reported in this issue of the Journal of Clinical Microbiology (L. Olarte et al., J Clin Microbiol 55:724–734, 2017, https://doi.org/10.1128/JCM.01778-16 ) underscore the limitations of pneumococcal vaccines that target the polysaccharide capsule.
No takes yet. Share an insight, caveat, or question.
Richter et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: